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Abstract: 
Quasi-experimental methods have proliferated over the last two decades, as researchers develop 
causal inference tools for settings in which randomization is infeasible. Two popular such 
methods, difference-in-differences (DID) and comparative interrupted time series (CITS), 
compare observations before and after an intervention in a treated group to an untreated 
comparison group observed over the same period. Both methods rely on strong, untestable 
counterfactual assumptions. Despite their similarities, the methodological literature on CITS 
lacks the mathematical formality of DID. In this paper, we use the potential outcomes framework 
to formalize two versions of CITS — a general version described by Bloom (2005) and a linear 
version often used in health services research. We then compare these to two corresponding DID 
formulations— one with time fixed effects and one with time fixed effects and group trends. We 
also re-analyze three previously published studies using these methods. We demonstrate that the 
most general versions of CITS and DID impute the same counterfactuals and estimate the same 
treatment effects. The only difference between these two designs is the language used to describe 
them and their popularity in distinct disciplines. We also show that these designs diverge when 
one constrains them using linearity (CITS) or parallel trends (DID). We recommend defaulting to 
the more flexible versions and provide advice to practitioners on choosing between the more 
constrained versions by considering the data-generating mechanism. We also recommend greater 
attention to specifying the outcome model and counterfactuals in papers, allowing for transparent 
evaluation of the plausibility of causal assumptions. 
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Section I: Introduction 
Methods for causal inference using observational data have proliferated in recent decades, as 
researchers seek to estimate causal quantities when randomization is infeasible.1–5  Difference-in-
differences (DID) is particularly popular thanks to its apparent conceptual simplicity. Many of 
the more than 300 papers evaluating the Affordable Care Act’s Medicaid expansion use DID.6 
DID compares the change in outcome before and after treatment in a treated group to the change 
over the same period in a comparison group that does not receive treatment. Comparative 
interrupted time series (CITS; also known as interrupted time series with a control or controlled 
interrupted time series) is superficially similar to DID. It also uses treated and comparison 
groups to compare changes before and after an intervention. The methods are so similar that 
some have asserted that they are the same.7,8   
However, proponents of DID and CITS each strongly prefer their respective methods, 
and these preferences tend to be disciplinary. Clinical epidemiology and education policy 
researchers gravitate to CITS, while economists and health policy researchers tend to use DID. 
Causal inference texts in economics may exclude interrupted time series or comparative 
interrupted time series.9,10  In contrast, a recent paper about quasi-experimental methods 
suggested that DID is “weak design” while CITS is a “strong design”.11 In dueling commentaries 
in the International Journal of Clinical Epidemiology, economists12 argued that a paper on 
rigorous CITS was inadequate because it failed to cite the DID literature. They claimed CITS 
was another name for DID and concluded that this omission misled readers about identification 
concerns raised in the DID literature. In a rebuttal, the authors of the original paper maintained 
that CITS is “regarded as a more powerful design than DID.”13  
Both DID and CITS come in many flavors, and, to add to the confusion, education policy 
and health services researchers often define CITS differently. The education policy literature 
defines CITS more generally than the health services literature. In this paper, we discuss two 
common versions of each design. For DID, we consider DID with time fixed effects (“FE DID”) 
and DID with both time fixed effects and group-specific pre-trends (“FE DID with group 
trends”). For CITS, we consider a generalized CITS (“general CITS”) and a fully linear version 
of CITS (“linear CITS”). 
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We briefly describe these methods here, deferring the details to subsequent sections. 
Linear CITS fits straight lines through the pre-period outcomes of the treated and comparison 
groups and assumes that the post-period change in the comparison group’s intercept and slope 
would also occur in the treated group in the absence of treatment. General CITS replaces the 
intercept and slope change assumption with the assumption that the difference between the 
observed and extrapolated outcomes of the comparison group at each post-period timepoint 
would hold in the treated group in the absence of treatment. FE DID uses time fixed effects to 
capture a common time trend and assumes the pre-period difference between treated and 
comparison groups would remain the same in the post-period in the absence of treatment. FE 
DID with group time trends adds a linearly growing difference between the two groups, which it 
extrapolates from the pre- to post-period (Figure 1). All four target estimands are the average 
effect of treatment on the treated (ATT). 
In some situations, only one method is feasible. FE DID requires only two observation 
points (one in the pre-period and one in the post-period), while FE DID with group trends and 
general CITS require at least five observation points (at least four pre and one post), and linear 
CITS requires at least eight (four pre and four post). DID can estimate a single treatment effect 
or a time-varying effect at each post-period time point (!""(")). General CITS also estimates the 
ATT at each post-period time point, while linear CITS estimates an intercept and slope shift. 
Many who prefer linear CITS cite the ability to estimate both immediate and sustained effects as 
an advantage of the method. Linear CITS does easily give the magnitude and direction of the 
growing treatment effect, while DID and general CITS’s time-varying treatment effects are not 
as amenable to easy summaries.  
Critics of DID state say the method is overly simplistic, restrictive, and inflexible because 
it fails to account for historical trends in the outcome.11,13,14 In the specification of DID with two 
time points per group, it is true that this design precludes adjustment for (or examination of) 
differential outcome trends prior to intervention. However, most DID studies include more than 
two time points. The counterfactual assumption of DID states that the average change in 
outcome in the two groups from pre- to post-period would have been the same if not for 
treatment. In practice, most researchers typically impose a more restrictive version of this 
assumption — the parallel evolution of untreated potential outcomes at all pre- and post-period 
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time points, referred to as the “parallel trends” assumption. However, several alternative model 
specifications for DID relax this assumption,15,16  including modeling group-specific trends.9 
All four designs assume additivity — that one can add the change in the comparison 
group to the treatment group’s pre-period outcomes to construct its counterfactual untreated post-
period outcomes. But their linearity assumptions vary. FE DID does not require any parametric 
model for the outcome. And FE DID with group trends assumes only that the difference between 
the two groups grows linearly. By contrast, both versions of CITS assume that the outcome trend 
is linear: general CITS assumes linearity in the pre-period trend only, while linear CITS assumes 
linearity in both the pre- and post-period trends. Critics of CITS argue that it makes unnecessary 
linearity assumptions. The upside, however, is a way out of DID’s parallel pre-trends restriction, 
because CITS explicitly models differential outcome trends. CITS extrapolates pre-period 
outcome trends to construct post-period counterfactual outcomes. Deviations from linearity in 
either period can lead to bias.17  
In its simplest version, DID can be estimated with the 2x2 table of treated/comparison 
and pre-/post-period average outcomes. However, most applied DID studies use multiple 
observations in the pre- and post-periods and time fixed effects to account for overall outcome 
trends. With continuous outcomes, DID models can be estimated via linear regression or non-
parametric approaches, while general and linear CITS require linear regression. Non-linear 
regression models for other outcome types are substantially more complicated to interpret, and 
we do not address them in this paper. Table 1 summaries the basics of functional form, 
extrapolation, and treatment effect estimation.  
Despite these critiques and differences, the literature does not offer clear guidance on 
instances where one design is more appropriate. This paper formalizes DID and CITS to enable a 
clear comparison. In Section II, we define the untreated potential outcome models of the four 
designs. In Section III, we provide three empirical examples illustrating the consequences of 
choosing CITS versus DID. As we demonstrate in Section II and III, the general forms of CITS 
and DID produce the same counterfactuals and the same treatment effect estimates. The only 
differences are language and disciplinary culture. In Section IV, we conclude with guidance on 
how to use each study design and improve reporting of analyses that use these models. We 
recommend that researchers use the more flexible version of these two designs, unless there is a 
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good reason to choose one of the more constrained versions, and always state their causal and 
statistical assumptions clearly. 
Section II: Comparison of Study Designs’ Potential Outcomes 
We begin by defining potential outcomes and constructing counterfactual outcomes in each 
design. Suppose the true data-generating model is # ∼ (&/2)$ in the comparison group and # ∼(&/3)$ in the treated group. The overall trends in both groups are non-linear and the differential 
growth between the two groups is also non-linear. The data-generating model does not change 
from the pre-period to the post-period, and the intervention has no effect on outcomes. We show 
how different models would construct the treated group’s untreated potential outcomes in the 
post-period (i.e., the counterfactual outcomes). In Figure 1, we plot true outcomes (dots) and 
model extrapolations (the lines) for the comparison group (blue) and treated group (purple).  
Let +% be the untreated potential outcome, & be time (with & < &% indicating the pre-
period and & ≥ &% the post-period), / be the parameters governing pre-period outcomes, and /˘ be 
the parameters governing post-period outcomes. We use superscripts to indicate group— 0 for 
the comparison group and 1 for the treated group. In each study design, the target estimand is the 
average effect of treatment on the treated (!""), which is defined as the difference between the 
observed (treated) and counterfactual (untreated) outcomes in the treatment group during the 
post-period. 
 General formulation of CITS 
The following version of CITS is found in Bloom and Riccio’s 2005 analysis of the Jobs-
Plus program:18 separate lines are fit through the pre-period outcomes of the comparison and 
treated groups and then extrapolated into the post-period for both groups. The counterfactual is 
constructed by first measuring the distance from the extrapolated line to the observed post-period 
outcomes in the comparison group at each post-period time point, & ≥ &%. Then, these distances 
are added to the extrapolated line for the comparison group at each time point. The comparison 
group’s untreated potential outcomes are 
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1[+"%] = /%% + /&%& + 6 /˘'%(')"! , 
and the treated group’s untreated potential outcomes are 
1[+"%] = /%% + /%%& + 6 /˘'%*')"! + /%& + /&&&. 
The parameters /%& and /&& are the differential intercept and slope of the treated group relative to 
the comparison group. In this version of CITS, we construct a counterfactual outcome at each 
post-period time & ≥ &% using the /'%˘  parameters. In Panel A of Figure 1, we see that the linear 
model of CITS is a reasonable fit to the pre-period data of both groups. Although this model has 
additional flexibility in the post-period to capture the non-linear trend in the comparison group, it 
does not capture the (non-linearly) growing gap between treated and comparison groups because 
of the underlying linearity extrapolation. 
Linear Formulation of CITS 
The fully linear version of CITS also fits lines through each group’s pre-period outcomes and 
extrapolates those lines into the post-period. Instead of measuring the distance from each point in 
the post-period to the extrapolated line, linear CITS fits another line through the comparison 
group’s post-period outcomes. The counterfactual is constructed by adding the comparison 
group’s pre-to-post differences in intercept and slope to the linear extrapolation of the treated 
group. The comparison group’s untreated potential outcomes are 1[+"%] = /%% + /&%& + 8/9%% +	/9&%&;<{","!} 
and the treated group’s untreated potential outcomes are 1[+"%] = /%% + /&%& + 8/9%% +	/9%%&;<{","!} + /%& + /&&&. 
Here, /%% and /&% are the pre-period intercept and slope for the comparison group, /9%% and /9&%are 
the change in intercept and slope for the comparison group in the post period, and /%& and /&& are 
the differential intercept and slope in the treated group. 
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Because the generated outcomes are reasonably linear within each group during the pre-period 
and because the linear version of CITS estimates a different line in each group and study period, 
the linear version of CITS fits the pre-period outcomes fairly well (Figure 1, Panel B). However, 
the non-linearity is more apparent in the post-period, as is the non-linearly growing difference 
between the two groups. 
DID with time fixed effects 
DID with time fixed effects (FE DID) assumes a constant difference between the treated and 
comparison groups. FE DID measures the average level change from the pre-period to the post-
period in the comparison group. To construct the counterfactual, FE DID assumes that the same 
change would have been seen in the treated group absent treatment. 
In the formulation of the potential outcomes for FE DID, we use =" to represent the time 
fixed effects, which are estimated throughout the pre- and post-period. The untreated potential 
outcomes in the comparison group are 1[+"%] = /%% + /%%˘ + =" , 
and the untreated potential outcomes in the treated group are 1[+"%] = /%% + /%%˘ <{","!} + /%& + ="	. 
 In this model, /%% and /%%˘  are the average level of the comparison group in the pre- and post-
period, respectively and /%& is the differential level of the treated group in the pre-period. In 
Figure 1, Panel C, we see the “parallel pre-trends” or constant difference assumption of DID. 
Because this, the FE DID fails to capture the growing difference between the two groups. 
DID with time fixed effects and group-specific trends 
Unlike FE DID, FE DID with group-specific trends allows the treated group to have a (linearly) 
diverging trend relative to the comparison group in the pre-period, which is then extrapolated 
into the post-period. The linear differential time trend is net of the average time trend captured by 
the time fixed effects. Like FE DID, the analysis assumes that the average level change in the 
comparison group would occur in the treated group absent treatment. But unlike FE DID, the 
	 8 
Fry & Hatfield, 2020 
counterfactual is constructed by first extrapolating the pre-period differential trends. The 
untreated potential outcomes in the comparison group are 1[+"%] = /%% + /%%˘ <{","!} + =" , 
and the untreated potential outcomes in the treated group are 1[+"%] = /%% + /%%˘ <{","!} + /%& + /&&& + =" . 
Like FE DID, this captures a level difference between treated and comparison in the pre-period 
(/%&) and an average change in the comparison group in the post-period (/%%˘ ). Unlike FE DID, this 
adds a differential linear trend in the pre-period (/&&). Here, there is only one trend estimate 
because of the time fixed effects.  
In our simulated data, the true data-generating model includes a differential trend in 
treated and comparison groups, so accounting for this improves the model fit in the pre-period 
(Figure 1, Panel D). In addition, this model’s counterfactual includes the growing differential 
between the two groups in a way that the FE DID model cannot.  
This counterfactual construction is identical to that of general CITS because the fixed 
effects are not being extrapolated into the post-period. The extrapolation occurring in FE DID 
with group trends is a differential linear time trend, which is the same extrapolation in general 
CITS. The difference is the assumption made about the pre-period outcome. In general CITS, the 
outcome’s trend is assumed to be linear, but FE DID with group trends assumes the difference 
between the groups is growing linearly. 
Section III: Empirical Examples 
In the following, we re-reanalyze data from three papers, compare our findings to the original 
results, explore differences in treatment effects across study designs, and discuss the how 
researchers might choose between DID and CITS. We fit four models to each dataset 1) FE DID, 
2) FE DID with group trends, 3) general CITS, and 4) linear CITS. In both DID formulations, we 
estimate time-varying treatment effects. In addition to plotting model fits and treatment effects, 
we make event study plots, which show the adjusted differential change in outcomes between 
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treated and comparison groups in each time period relative to a single pre-period reference time. 
These provide a useful visual of how outcomes differentially evolve in the two groups during 
both pre- and post-periods but are not appropriate for formal inference. 	
Medicaid expansion’s spillover to the criminal justice system 
Fry, McGuire, and Frank19  conduct three case studies to estimate the impact of the ACA’s 
Medicaid expansion on rates of return to county jails. The rationale for linking medical insurance 
coverage to jail involvement is the confluence of substance use disorders, serious mental health 
diagnoses, and uninsurance among people in jails. Each case study compares the change in 
outcomes for a county in a state that expanded Medicaid to the change in outcomes for a county 
in a state that did not expand Medicaid. For brevity, we re-analyze only one of the three case 
studies and only one outcome, the probability of re-arrest. 
The authors of the original paper briefly discuss the rationale for choosing a CITS design, 
“Given the drivers of the outcome in this study (e.g., policing practices, criminal justice 
practices, and access to behavioral health services) and how they may vary between the counties, 
assuming linearity in the evolution of the outcomes in each of the two groups seems more 
reasonable than assuming that they evolve in the same average way over time” (page 16). The 
authors also provided qualitative information of differential demographics, access to behavioral 
health resources, policing practices, and coordination between the behavioral health and criminal 
justice systems in the study counties. Thus, assuming outcomes evolve in the same way in 
treatment and comparison groups was deemed unreasonable. 
The difference in the pre-period trends is large and approximately linear (Figure 2, Panel 
A). The diverging pre-period outcomes suggest that FE DID is not an appropriate study design 
but accounting for the pre-period divergence via CITS or FE DID with group trends may be 
more appropriate. After Medicaid expansion, there is an immediate decrease and a flattening of 
the differential trend, suggesting that CITS will estimate negative differential changes in both 
intercept and slope. 
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Indeed, using linear CITS, we estimate that Medicaid expansion reduces the probability 
of any re-arrest by 2.00 (95% CI: 1.62, 2.34) percentage points in the first month after expansion 
(i.e., the differential intercept change), and the decline grows by 0.07 (95% CI: 0.06, 0.08) 
percentage points each month (i.e., the differential slope change). By contrast, using FE DID, 
which does not account for the diverging pre-trends, the estimated effect at the midpoint of the 
post-period is 2.32 percentage points (or 84%) smaller than the other estimates, and the treatment 
effect grows in a positive direction. 
Diverging pre-period trends is one piece; the other is the linearity of the differential 
evolution in the post-period. As expected, FE DID with group trends and general CITS estimates 
are identical (Figure 2, Panel B). They also closely track the linear CITS estimates, which is also 
expected, given the approximately linear evolution of the differential changes in the post-period 
(Figure 2, Panel A). 
Drivers of recidivism, such as policing and behavioral health treatment availability, differ 
across counties and time. Thus, FE DID’s assumption of a (counterfactual) constant difference in 
expansion and non-expansion counties is not reasonable. By contrast, the differential outcome 
trends are approximately linear in both pre- and post-periods, so linear CITS, general CITS, and 
FE DID with group trends all produce similar estimates. The crucial piece in this example is 
accounting for diverging pre-period trends (with linear CITS, general CITS, or FE DID with 
group trends). The data that support the findings of this reanalysis are available on request from 
the corresponding author.  
Medicaid expansion and naloxone prescriptions 
Frank and Fry20 compare the change total in naloxone prescriptions before and after Medicaid 
expansion in expansion and non-expansion states. The rationale for linking insurance coverage to 
naloxone is that increased financial access will increase treatment with naloxone. While the 
authors do not provide any explicit rationale for choosing DID, they write, “the number of 
naloxone prescriptions paid for by Medicaid was essentially identical in expansion states 
compared to non-expansion states” and compare the unadjusted outcome trends for both groups.  
The event study plot in Figure 3 (Panel A) shows that the differential trend hovers very 
close to zero in the pre-period, which supports FE DID’s assumption of no differential trends. In 
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the post-period, the outcomes diverge non-linearly, which suggests that a linear CITS model will 
not capture this dynamic. General CITS and FE DID with group trends both flexibly model the 
post-period, so we expect that they will produce similar estimates to the FE DID model, given 
the lack of differential pre-period trends. 
Indeed, the linear CITS model estimates a differential decrease of 66.8 (95% CI: 7.6, 
125.9) naloxone prescriptions in the quarter after expansion, with a growing increase of 25.4 
(95% CI: 7.1, 43.7) prescriptions in each quarter thereafter. At the beginning and end of the post-
period, the linear CITS estimates differ substantially from the other three models (Figure 3, Panel 
B). Again, general CITS and FE DID with group trends produce identical estimates (Figure 3, 
Panel B), and because of the lack of differential pre-trends, the FE DID estimates are also very 
similar.  
Drivers of naloxone prescriptions include the prevalence of opioid use disorder and laws 
affecting access, such as the ability of doctors to prescribe naloxone to a friend or family 
member. Although these vary across both states and time, and anecdotal evidence suggests some 
states expanded Medicaid partly in response to growing opioid use disorder, the event study plot 
shows no differential evolution of naloxone prescriptions in the pre-period. However, that plot 
does show non-linear differential trends in the post-period. The crucial piece in this example is 
flexibly modeling the post-period differential trends (with general CITS, FE DID, or FE DID 
with group trends).  
Reformulation of OxyContin and the incidence of Hepatitis C 
Powell, Alpert, and Pacula22 explore the relationship between the 2009 reformulation of 
OxyContin to an abuse-deterrent form and changes in the incidence of acute Hepatitis C (HCV) 
infections. The rationale for linking OxyContin reformulation to HCV is that people will switch 
from OxyContin to illicit opioids, including intravenous heroin, and be exposed to bloodborne 
illnesses like HCV. The reformulation of OxyContin was a national policy implemented in all 
U.S. states, so there is no unexposed comparison group. Instead, the authors used a continuous 
measure of each state’s rate of OxyContin abuse or misuse in the pre-period, reasoning that this 
is a proxy for the “strength” of the reformulation’s impact. Using a continuous exposure variable 
assumes that the relationship between initial OxyContin abuse or misuse and the treatment 
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impact is linear. In addition, the original study drew inferential conclusions from the event study, 
but the counterfactual assumptions of this approach were not formalized. 
The authors write, “The testable assumption is that OxyContin misuse rates were not 
predictive of hepatitis C infection trends before the reformulation. Studying the effect of a policy 
exposure both before and after the intervention in an event study is recommended when using 
difference-in-differences designs to study health policy.” (page 289) While counterfactual 
assumptions are not testable, this language suggests the DID parallel pre-trends assumption and 
the procedures often used to “test” this assumption. Powell, et al. conclude that the reformulation 
of OxyContin did not change the HCV cases in the year after formulation but did in each 
subsequent year (see Exhibit 4 of the original paper).22 
Panel A of Figure 4 suggests modest differential pre-period trends and some non-
linearities in the post-period differential evolution. Together, these suggest that both accounting 
for pre-period trends and flexibly modeling the post-period differential evolution will be 
important. Thus, we expect all four models will estimate similar treatment effects.  
Using FE DID, we estimate an increase in the rate of HCV infections in years 2 through 5 
after reformulation (Figure 4, Panel B). When we account for diverging pre-period trends with 
general CITS and FE DID with group trends, our estimates get slightly smaller in years 4 and 5 
after reformulation. The decrease in estimates when we model group-specific pre-period trends 
demonstrates the impact of differential trends, even when they are not statistically different from 
zero. 
Linear CITS also accounts for the difference in pre-period trends and thus also results in 
smaller effect estimates than the FE DID. Although the linear CITS estimates look fairly similar 
to those produced by the other three study designs, modeling the post-period trend as linear 
misses the slight increase in years 2 and 3 after reformulation that the more flexible modeling of 
FE DID and general CITS. The result is that neither the intercept nor slope estimates in linear 
CITS are statistically significant. 
Prior to the reformulation of OxyContin, there were small differential trends in HCV 
rates, perhaps driven by differential rates of intravenous drug use, risky sexual behavior, and 
access to services for the detection and treatment of HCV, which all vary across states and time. 
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It is unclear whether acute HCV incidence would have evolved similarly in “high” and “low” 
exposure states in the absence of reformulation. In our re-analyses, general and linear CITS and 
FE DID with group trends all accounted for the divergent pre-period trends, but linear CITS 
missed dynamics in the treatment effect. Accounting for pre-period differential trends and 
flexibly modeling the treatment effect in the post-period were both important in this example, but 
the impacts were subtle compared to Fry et al. (2020).19  
Section IV: Conclusion 
Through mathematical formalization of the models and careful examination of the counterfactual 
assumptions, we have highlighted the differences and similarities among four models: general 
CITS frequently used in education policy research, linear CITS used most often in health 
services research, DID with time fixed effects, and DID with time fixed effects and group-
specific trends. The counterfactual is constructed similarly in all four designs — by assuming 
that the change in the comparison group can stand in for the change in the treated group absent 
treatment. 
 In their most general forms, CITS (i.e., general CITS) and DID (i.e., FE DID with group 
trends) produce the same counterfactuals and estimate the same treatment effects. The only 
difference between these two designs is disciplinary preferences for the language to describe 
them. Because of their flexibility to model differential pre-period trends and non-linear evolution 
of the treatment effect, we suggest that researchers consider general CITS or FE DID with group 
trends first. 
When we lean into each design’s respective constraints (linearity for CITS and a constant 
difference for DID), the counterfactuals begin to differ. The choice between these two less-
flexible models should rely on content expertise about the data-generating model. If one believes 
the evolution of the outcome and its confounders is linear over the entire study period, then 
linear CITS may be preferable. If one believes that the differential evolution in the two groups’ 
untreated potential outcomes is zero, FE DID may be preferable. As recommended by Bilinksi 
and Hatfield (2020)23, one way to assess the plausibility of the “parallel pre-trends” assumption 
of DID is to compare the estimates of FE DID and FE DID with group trends.  
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While we believe model choice should rely on careful consideration of the counterfactual 
assumption and the evolution of the outcome, visual devices like adjusted event study plots can 
be helpful as well. Evidence of adjusted, differential pre-period trends in an event study plot may 
suggest that a DID may not be appropriate, as seen in the re-analysis of Fry, et al.19 and Powell, 
et al.22. However, where non-linear outcome trends are present, imposing the linearity 
assumption of CITS may not fully capture the treatment effect over time as seen in the re-
analysis of Frank & Fry20 and Powell, et al.22 
In sum, researchers considering a two-group, pre-post study design should opt for a 
flexible model, whether they call it general CITS or FE DID with group trends, unless there is a 
strong reason for choosing a more constrained version. In addition, researchers should provide 
detailed model specifications and counterfactual assumptions in their empirical work. This 
allows for a transparent evaluation of the plausibility of these assumptions and clear 
interpretation of the resulting causal effect estimates. 
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Table 1. Comparison of Features of CITS and DID   
Design # Time Points Functional Form Extrapolation Linearity Assumption Treatment effect estimation 
General CITS ≥ 5 Linear, additive Linear Pre-period trend #$$(");  
Linear regression 
Linear CITS ≥ 8 Linear, additive Linear Pre & post-period trend Intercept, slope;  
Linear regression 
FE DID w/ group 
trends 
≥ 5 Linear, additive Linear2 Differential growth between 
groups 
#$$(");  
Linear regression/non-parametric 
FE DID ≥ 2 Additive Zero difference None #$$(");  
Linear regression/non-parametric 
 
1Can be used to construct an !""(") 
2Linearity is assumed for the evolution of the difference between the treated and control, rather than for the outcome trend itself. 
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Figure 1. Comparison of counterfactual scenarios in non-linear models 
 
NOTES: The untreated group’s true outcomes (blue dots) are generated from the model, ! ∼ #!"$", and the treated group’s true outcomes in the pre-period (purple dots) 
are generated from the model, ! ∼ #!#$". The treated group’s true, unobservable post-period untreated outcomes are the empty dots. Lines are the modeled outcomes 
using linear regression for each study design. 
 
Comparison	
Treated	
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Figure 2. Comparison of Estimates Across Study Designs - Fry et al, 2020 
 
SOURCES/NOTES: Sources Authors’ re-analysis of booking and release data from Fry et al., 2020. Notes Panel A is an event study 
plot, where the adjusted differential in outcome between the treated group and comparison group relative to the time of intervention is 
estimated for each time period before and after Medicaid expansion. Panel B provides time-varying estimates for each month after 
Medicaid for FE DID, FE DID with group trends, general CITS, and linear CITS. Covariate adjustment is the same for each model 
presented in both Panels A and B and is exactly the same as the covariate adjustment used in Fry et al., 2020.  
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 Figure 3. Comparison of Estimates Across Study Designs - Frank & Fry, 2019 
 
SOURCES/NOTES: Sources Authors’ re-analysis of Medicaid covered naloxone prescriptions from Frank & Fry, 2019. Notes Panel A 
is an event study plot, where the adjusted differential in outcome between the treated group and comparison group relative to the time of 
intervention is estimated for each time period before and after Medicaid expansion. Panel B provides time-varying estimates for each 
month after Medicaid for FE DID, FE DID with group trends, general CITS, and linear CITS. Covariate adjustment is the same for each 
model presented in both Panels A and B and is exactly the same as the covariate adjustment used in Frank & Fry, 2019. 
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  Figure 4. Comparison of Estimates Across Study Designs - Powell, et al., 2019 
 
SOURCES/NOTES: Sources Authors’ re-analysis of acute HCV incidence from Powell et al., 2019. Notes Panel A is an event study 
plot, where the adjusted differential in outcome between the treated group and comparison group relative to the time of intervention is 
estimated for each time period before and after Medicaid expansion. Panel B provides time-varying estimates for each month after 
Medicaid for FE DID, FE DID with group trends, general CITS, and linear CITS. Covariate adjustment is the same for each model 
presented in both Panels A and B and is exactly the same as the covariate adjustment used in Powell et al., 2019. Unlike Powell et al., 
2019 who use a continuous treatment variable, we use a binary exposure variable with the cutoff for “high exposure” being the median 
OxyContin misuse rate in the pre-period. 
 
 
 
